{"id":58854,"date":"2026-03-05T15:44:25","date_gmt":"2026-03-05T07:44:25","guid":{"rendered":"https:\/\/flcube.com\/?p=58854"},"modified":"2026-03-05T15:44:26","modified_gmt":"2026-03-05T07:44:26","slug":"bayer-reports-eur-45-6-billion-2025-sales-nubeqa-and-kerendia-drive-pharma-growth-amid-xarelto-patent-cliff","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58854","title":{"rendered":"Bayer Reports EUR 45.6\u202fBillion 2025 Sales \u2013 Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff"},"content":{"rendered":"\n

Bayer AG<\/strong> (ETR: BAYN<\/a>) released its 2025 financial results<\/strong>, recording EUR 45.6\u202fbillion<\/strong> (USD\u202f52.84\u202fbillion) in group sales, up 1.1%<\/strong> on a currency\u2011 and portfolio\u2011adjusted basis year\u2011on\u2011year. The pharmaceutical division delivered 1.7% growth<\/strong> driven by oncology and cardiorenal blockbusters, offsetting steep declines in mature cardiovascular and ophthalmology franchises.<\/p>\n\n\n\n

Regional Performance<\/h2>\n\n\n\n
Region<\/th>Sales (EUR\u202fM)<\/th>Change (Fx & p adj.)<\/th>Commentary<\/th><\/tr><\/thead>
North America<\/strong><\/td>16,725<\/td>+5.1%<\/strong><\/td>Strongest growth region; pharma pricing power offset consumer softness<\/td><\/tr>
Latin America<\/strong><\/td>7,831<\/td>+4.7%<\/strong><\/td>Market expansion in Consumer Health; currency tailwinds<\/td><\/tr>
Europe\/Middle East\/Africa<\/strong><\/td>13,501<\/td>\u20133.5%<\/strong><\/td>Xarelto generic erosion; consumer destocking<\/td><\/tr>
Asia\/Pacific<\/strong><\/td>7,518<\/td>\u20132.8%<\/strong><\/td>China macro weakness; Eylea biosimilar competition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pharmaceuticals Division \u2013 Product\u2011Level Breakdown<\/h2>\n\n\n\n
Product<\/th>Franchise<\/th>2025 Sales (EUR\u202fM)<\/th>Change (YOY)<\/th>Driver\/Headwind<\/th><\/tr><\/thead>
Nubeqa<\/strong> (darolutamide)<\/td>Oncology<\/td>2,385 (USD\u202f2,764)<\/td>+62.4%<\/strong><\/td>Metastatic prostate cancer label expansion; urology market share gains<\/td><\/tr>
Kerendia<\/strong> (finerenone)<\/td>Cardiorenal<\/td>829 (USD\u202f961)<\/td>+88.0%<\/strong><\/td>Diabetic kidney disease guideline inclusion; cardio\u2011renal benefit data<\/td><\/tr>
Xarelto<\/strong> (rivaroxaban)<\/td>Cardiovascular<\/td>2,344 (USD\u202f2,716)<\/td>\u201331.6%<\/strong><\/td>U.S. patent expiry (2024); generic erosion accelerating<\/td><\/tr>
Eylea<\/strong> (aflibercept)<\/td>Ophthalmology<\/td>3,110 (USD\u202f3,604)<\/td>\u20133.7%<\/strong><\/td>Biosimilar entry (aflibercept\u2011szzs); intravitreal market share loss<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Division Total:<\/strong> EUR\u202f17,829\u202fmillion (+1.7% Fx & p adj.<\/strong>)<\/p>\n\n\n\n

Consumer Health Division<\/h2>\n\n\n\n
Metric<\/th>2025 Performance<\/th><\/tr><\/thead>
Sales<\/strong><\/td>EUR\u202f5,802\u202fmillion (USD\u202f6,723\u202fmillion)<\/td><\/tr>
Growth<\/strong><\/td>\u20130.1%<\/strong> (flat)<\/td><\/tr>
Pricing Impact<\/strong><\/td>Moderate contribution; decelerating vs. prior years<\/td><\/tr>
Volume Trend<\/strong><\/td>Stabilized overall<\/td><\/tr>
Regional Split<\/strong><\/td>Growth: EMEA, Latin America; Decline: U.S., China (macro pressures)<\/td><\/tr>
Category Performance<\/strong><\/td>All categories positive; Allergy\/Cough\/Cold only moderate gains<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Outlook & Investor Takeaways<\/h2>\n\n\n\n